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Abstract
Background: PD-L1 is a glycoprotein from the family of T-cell co-stimulatory molecules that are constitutively
expressed by macrophages. Aberrant expression of PD-L1 is observed in human cancers associated with
inhibition of the tumor-directed T-cell immune response. There are few reports in the literature evaluating
PD-L1 expression in association to prognosis specifically in renal cell cancer clear cell type (RCC-CC).
Methods: Immunohistochemistry using a PD-L1 polyclonal antibody was performed on a tissue microarray
(TMA) that contained 115 surgical specimens of RCC-CC. Cases were classified based on the absence or
presence of staining intensity in the cytoplasm and membranes of the tumor cells. Statistical analysis was
used to determine the association of PD-L1 expression with classic prognostic factors and tumor recurrence.
Results: PD-L1 expression was positive in 56.5 % of tumors. The univariate analysis showed a correlation between PD-L1
expression and nuclear Fuhrman grade (p = 0.021) and microvascular tumor embolization (p = 0.039). One hundred and
four patients were monitored for a mean time of 115.7 months. Seventeen patients (16.3 %) suffered tumor recurrence.
Negative outcomes were associated with higher nuclear grade tumors, PD-L1 expression, and the presence of
microvascular invasion.
Conclusion: Our findings confirm that PD-L1 expression is an important prognostic factor in RCC-CC.
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Background
Recently, the capacity of neoplastic cells to evade immuno-
logical destruction became an additional checkpoint in
assessing the hallmarks of cancer [1]. T cells play the most
important role in this context; the recognition of tumor-
associated antigens by healthy T cells allows the activation
of a specific anti-tumor immune reaction. CD8+ effector T
cells, known as cytotoxic T lymphocytes (CTLs), are the
main players in this process. Two receptors, cytotoxic
T-lymphocyte-associated antigen 4 (CTLA4) and pro-
grammed cell death protein 1 (PD-1), have been ac-
tively studied in cancer for their potential roles as
inhibitory receptors. Blockage of these receptors by
antibodies has been studied in numerous clinical trials
with promising results [2, 3].
PD-1 is a 288-amino acid cell-surface protein. PD-1 binds
two ligands, PD-L1 and PD-L2, which negatively regulate
the immune response. The expression of PD-L1 (also
known as B7-H1) on tumor cells leads to the inhibition of
the T cell-mediated immune response against cancer,
thereby enabling tumor progression and metastasis [4, 5].
Expression of PD-L1 has been correlated with poor clin-
ical outcomes in a number of human cancers [6], includ-
ing renal cell cancer (RCC) [7]. As a result, it has been
considered a potential predictive biomarker and has in-
spired new drug development designed to block PD-1.
Immunotherapy was the leading strategy for treating
RCC until recently, when targeted inhibitors of the
VEGF (Vascular endothelial growth factor) and mTOR
pathway began to show promising results. These thera-
peutic inhibitors increased progression-free and overall
survival rates, but failed to show a durable response.
Blocking the PD-1-PD-L1 interaction with monoclonal
antibodies, however, restores the activity of T cells within
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the tumor microenvironment and has been shown to re-
sult in a significant and sustained antitumor response in
clinical trials [8].
Our aim is to study the PD-L1 expression in RCC
clear cell type (RCC-CC) and how that expression corre-
lates with prognostic factors and tumor recurrence.
Methods
The Institutional Internal Review Board approved this
study (process number 1,034,579). We retrospectively
analyzed surgical specimens from 148 patients diagnosed
with localized (NX-0 M0) RCC-CC who underwent rad-
ical or conservative renal surgery (partial nephrectomy
or tumor enucleation) between 1988 and 2006 at our in-
stitution. Data and adequate material for examination
were available for 115 patients, and the clinical and
pathological characteristics are shown in Table 1. For
staging purposes, lymph node dissection was limited to
the hilar region in those who underwent radical neph-
rectomy. The same surgeon (MS) operated on all pa-
tients and all pathological analyses were performed by
the same uropathologist (KRML). Patients with systemic
metastatic disease at the time of surgery were excluded
from the study. For each patient, the analyzed clinical
and pathological characteristics included age, gender,
symptoms at initial presentation, tumor size, pT stage
(2010 TNM classification), Fuhrman nuclear grade, nu-
cleolar grade as recently recommended by International
Society of Urological Pathology (ISUP) [9], coagulative
tumor necrosis, and microvascular invasion. Following
surgery, all patients appeared for regular follow-up visits
based on their staging. Low-risk patients returned for
semi-annual physical examinations and routine blood
tests in addition to annual chest radiography and ab-
dominal computed tomography. Chest tomography,
bone scintigraphy, and brain imaging were conducted in
clinically applicable cases.
The tissue microarray (TMA) was constructed as pre-
viously described [10]. Using a precision mechanical sys-
tem (Beecher Instruments, Sun Prairie, WI), tissue
cylinders with a diameter of 0.6 mm were removed from
each patient’s paraffin block containing the RCC-CC
from specific areas, corresponding to the previously de-
marcated, most representative areas from respective
hematoxylin-eosin-stained slides. These cylinders were
transferred with 3-mm intervals to a recipient paraffin
block. Next, the tissue microarray recipient block was
cut into 3-μm histologic section, and this slide was used
for immunohistochemistry. Two tumor samples were
collected per patient, because it has been demonstrated
that analysis of 2 disks is comparable to the analysis of a
whole tissue section in more than 95 % of cases [11].
Immunohistochemical analysis was performed using
BOND III Leica equipment (Leica Biosystems) using
the polyclonal antibody anti-PD-L1 (ABCAM) in a
1:25 dilution.
Statistical analysis was performed using SPSS version
19.0 software. Differences between groups were evalu-
ated using a χ2 test. Time to recurrence was calculated
using the Kaplan–Meier method. The differences be-
tween the curves were measured using a log-rank test.
Two-tailed tests were used and a p-value <0.05 was con-
sidered to be significant.
Results
PD-L1 was diffusely expressed in the cytoplasm and
membrane of tumor cells in 65 (56.5 %) of assessed
cases. The staining was weak in 29 (44.6 %), moderate in
Table 1 Clinical and pathological characteristics of 115 patients
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15 (23.1 %) and strong in 21 (32.3 %) of the cases (Fig. 1).
For statistical analysis, we considered any intensity of
staining as positive and compared these results with cases
that were completely negative for staining. The univariate
analysis showed correlation between PD-L1 expression
and higher nuclear Fuhrman grade (p = 0.021) and micro-
vascular tumor embolization (p = 0.039). The results are
expressed in Table 2. Although there was no correlation
between PD-L1 expression and any other of the tested
negative prognostic factors, in the few cases in which
lymph node metastasis was present, PD-L1 was expressed
in 67 % of the cases. PD-L1 was also expressed in 83 % of
cases that developed distant metastasis and in 65 % of
cases that showed tumor recurrence.
One hundred and four patients were followed for a
mean time of 115.7 months. Seventeen (16.3 %) of the
followed cases suffered tumor recurrence. Tumor size
(8.6 cm vs 4.1 cm; p < 0.001), symptomatic presenta-
tion (p < 0.001), microvascular invasion (p < 0.001),
tumor necrosis (p = 0.007), tumor stage (pT2/pT3 vs
pT1, p < 0.001) and the presence of lymph node me-
tastasis (p < 0.001) were all factors that were related
to tumor recurrence (Table 3).
We have previously described that the Fuhrman nu-
clear grade and microvascular tumor invasion are
powerful predictors of outcome in RCC [12]. Consider-
ing these two important prognostic factors for localized
RCC, we built a Kaplan-Meier curve using these param-
eters with the addition of PD-L1 expression. Cases were
grouped as follows: 1. PD-L1 negative, no microvascular
tumor invasion and low Fuhrman nuclear grade; 2. Pres-
ence of one of any of these variables; 3. Presence of two
of any of these variables; and 4. Presence of all three var-
iables: PD-L1 expression, microvascular tumor invasion
and high Fuhrman nuclear grade. The curves are shown
in Fig. 2. There is clearly a higher rate of tumor recur-
rence in patients who were positive for these three poor
prognostic factors (p = 0.007).
Fourteen (12.2 %) patients died, 13 (92.9 %) of whom
died as a result of RCC progression. PD-L1 was positive
in 8 from these 13 (61.5 %) cases (p = 0.104). Although
the relationship is not statistically significant, the small
number of tumor-related deaths may have influenced
the negative result.
In conclusion, PD-L1 was diffusely expressed by
56.5 % of the cases related to higher nuclear Fuhrman
Fig. 1 Photomicrography showing PD-L1 immune-expression in RCC-CC. a Positive control, b negative control, c Positive - score 1, d Positive – score
2, e Positive – score 3
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grade (p = 0.021) and microvascular tumor embolization
(p = 0.039) in univariate analysis.
Discussion
PD-L1 expression has been studied as a biomarker of re-
sponse to the new PD-1/PD-L1 inhibitors in different tu-
mors, but its prognostic value is not yet well established.
Our study showed that PD-L1 was expressed in 56.5 %
of RCC-CC cases and positive expression was correlated
with a higher Fuhrman nuclear grade and microvascular
tumor embolization. In addition, PD-L1 analysis pro-
vided information about the relationship between tumor
outcome and higher rates of tumor recurrence when as-
sociated with these two other tested prognostic factors.
In 1999, Dong et al. described PD-L1 as a cell-surface
glycoprotein within the B7 family of T-cell co-stimulatory
molecules that is constitutively expressed by macrophage-
lineage cells [13]. Since then, studies have shown aberrant
expression of PD-L1 in various human cancers, including
breast, ovarian, lung, and colon cancer, in addition to
lymphoma and melanoma [14]. Tumor cells that express
PD-L1 have been shown to inhibit tumor-specific T-cell-
mediated immunity by inducing T-cell apoptosis, impairing
Table 2 Correlation between PD-L1 expression and prognostic
factors
PD-L1 neg PD-L1 pos p
Characteristics (N = 115)
Age 58.2 57.4 0.737
Gender
Female 9(37.5) 15(62.5) 0.507
Male 41(45.1) 50(54.9)
Tumor size (cm) 4.5 5.1 0.246
Presentation
Incidental 34(44.7) 42(55.3) 0.704
Symptomatic 16(41.0) 23(59.0)
Fuhrman nuclear grade
1,2 36(52.2) 33(47.8) 0.021
3,4 14(30.4) 32(69.6)
Nucleolar grade




Absent 41(49.4) 42(50.6) 0.039
Present 9(28.1) 23(71.9)
Tumor necrosis
Absent 41(45.1) 50(54.9) 0.507
Present 9(37.5) 15(62.5)
Tumor stage
pT1 38(47.5) 42(52.5) 0.188
pT2,3 12(34.3) 23(65.7)
Metastasis to lymph nodes
Absent 48(44.0) 61(56.0) 0.607
Present 2(33.3) 4(66.7)
Development of distant metastasis
Absent 49(45.0) 60(55.0) 0.174
Present 1(16.7) 5(83.3)
Tumor recurrence (N = 104)
Absent 39(44.8) 48(55.2) 0.468
Present 6(35.3) 11(64.7)
Table 3 Clinical and pathological characteristics of patients
considering tumor recurrence
Tumor recurrence (N = 104) No(87) Yes(17) p
Characteristics
Age (mean-yo) 57.7 60.1 0.436
Gender
Female 21(24.1) 3(17.6) 0.561
Male 66(75.9) 14(82.4)
Tumor size (mean-cm) 4.1 8.6 <0.001
Presentation
Incidental 64(73.6) 4(23.5) <0.001
Symptomatic 23(26.4) 13(76.5)
Fuhrman nuclear grade
1,2 57(65.5) 8(47.1) 0.150
3,4 30(34.5) 9(52.9)
Nucleolar grade




Absent 70(80.5) 5(29.4) <0.001
Present 17(19.5) 12(70.6)
Tumor necrosis
Absent 72(82.8) 9(52.9) 0.007
Present 15(17.2) 8(47.1)
Tumor stage
pT1 70(80.5) 5(29.4) <0.001
pT2,3 17(19.5) 12(70.6)
Metastasis to lymph nodes
Absent 86(98.9) 13(76.5) <0.001
Present 1(1.1) 4(23.5)
PDL1
Negative 39(44.8) 6(35.3) 0.468
Positive 48(55.2) 11(64.7)
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cytokine production, and diminishing the cytotoxicity of
activated T cells [15].
There are few reports in the literature evaluating the
relationship between PD-L1 expression and clinical
prognosis in RCC, and the majority of existing reports
relates expression with other known poor prognosis fac-
tors and negative outcome.
Thompson et al. were the first to study PD-L1 expres-
sion by immunohistochemistry in RCC, finding 24 % of
staining associated with adverse pathologic features, in-
cluding higher tumor stage, greater tumor size, a Fuhr-
man nuclear grade of 3 or 4, and tumor necrosis [16]. In
addition, by evaluating the expression levels of PD-L1
in tumor cells alone, in lymphocytes alone, or in
tumor and/or lymphocytes combined, researchers
have shown an association between PD-L1 positivity
with aggressive tumor behavior and increased risk of
death from RCC [17].
Choueiri et al. showed that PD-L1 expression is related
to shorter survival times in patients with metastatic RCC
who were receiving VEGF-targeted agents, therefore ar-
guing that PD-L1 expression should be considered in
the design of future clinical trials [18].
Interestingly a study published by Jilaveanu et al. [19]
compared PD-L1 in 34 cases of primary and metastatic
RCC showing no correlation between paired specimens.
They advocate that the result of primary tumor regarding
PD-L1 expression is not appropriate to predict response
to the new PD-L1 inhibitors.
In non-clear cell RCC patients with PD-L1 tumor ex-
pression is associated with higher tumor stage and grade
and worse clinical outcomes [20].
In breast cancer, PD-L1 was upregulated in 20 % of
cases and was related to poor-prognostic features such
as tumor size, high grade, estrogen and progesterone
negativity, Her2/Neu positivity and higher rates of cell
proliferation, although upregulation of PD-L1 was not
associated with survival of patients in this study [21].
In gastric cancer, PD-L1 was positively expressed in
50 % of cases associated with higher T stage, lymph-
node metastasis and overall survival [22].
A meta-analysis study of non-small cell lung cancer in-
dicated that PD-L1 expression is associated with tumor
differentiation and lower overall patient survival [23].
The fact that we used a TMA to indicate PD-L1 ex-
pression should be a point of criticism; however, in stud-
ies of other tumor markers, the representation of two
cores has been shown to generally be similar to a whole
tissue fragment, with the advantage of standardization in
the immunohistochemistry reaction [11]. The small
number of cases, particularly the small number of cancer
deaths, may reflect some percentage of error in TMA-
Fig. 2 Kaplan-Meier curve of tumor recurrence. The blue line represents tumors negative for PD-L1 with no microvascular tumor invasion and
low nuclear grade. The green line represents tumors with one of the following: PD-L1 expression, microvascular tumor invasion, or high nuclear
grade. The yellow line represents tumors with two of these variables, and the purple line represents tumors with all three unfavorable prognostic
factors (p = 0.007)
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based PD-L1 analysis, which may explain the absence of
a positive result regarding PD-L1 expression and tumor
prognosis in this statistical analysis.
Conclusion
In conclusion, this report confirms, using immunohisto-
chemistry, that PD-L1 expression represents a new
marker of prognosis in RCC-CC.
Abbreviation
RCC-CC: Renal cell cancer clear cell type; CTL: Cytotoxic T lymphocytes;
CTLA4: C ytotoxic T-lymphocyte-associated antigen 4; PD-1: Programmed cell
death protein 1; PD-L1: Programmed cell death protein ligand 1;
VEGF: Vascular endothelial growth factor; mTOR: Mammalian target of
rapamycin; TMA: Tissue microarray.
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